Sanofi and partners’ success with repurposed antibodies for Covid-19 depend on recruiting less critically ill patients
Country-wide lockdowns as a countermeasure against COVID-19 have severely affected the clinical development of new agents. Pharmaceutical companies and academic institutions have chosen to de-prioritize and suspend certain clinical trials or to defer enrollment to a later date.
Biopharmaceutical company MediciNova has plans to study its investigational drug, ibudilast (MN-166), to treat acute respiratory distress syndrome (ARDS) associated with Covid-19.
Sarclisa® (isatuximab-irfc) is a monoclonal antibody in combination with pomalidomide and dexamethasone (pom-dex) indicated for the treatment of multiple myeloma.
Biotechnology firm Novavax is set to start the human clinical trial of a Covid-19 vaccine candidate called NVX-CoV2373 in May.
Clinical trials, which are conducted in laboratories and designated centres, require the presence of professionals and constant monitoring of the enrolled subjects.
The US Food and Drug Administration (FDA) has granted approval for OncoImmune to conduct a Phase III clinical trial of CD24Fc to treat patients hospitalised with Covid-19.
Zelira Therapeutics has reported positive data from the Phase Ia/IIb clinical trial of medicinal cannabis for the treatment of insomnia.
DefenVid is an innovative nutraceutical of the lipofishin family. E-JUR-94013TM is the structural base of DefenVid, a bioderivative obtained from the species Trachurus trachurus (Atlantic horse mackerel).
Life sciences services provider IQVIA has introduced an open Covid-19 registry platform and technology-powered trial matching solution